Chemomab Therapeutics (CMMB) Cash from Operations Growth (3y) (2020 - 2023)
Chemomab Therapeutics (CMMB) Cash from Operations Growth (3y) (2020 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,839.48 Bn | 65,839.20 Bn | - | -5.07% |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 472.40 Bn | 467.61 Bn | 1.35 Bn | 33.08% |
| 5 | Vertex Pharmaceuticals | 122.23 Bn | 114.98 Bn | 2.59 Bn | 16.64% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -7.60% |
| 7 | Belite Bio | 62.46 Bn | 62.46 Bn | - | - |
| 8 | Argenx Se | 55.94 Bn | 50.76 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.52 Bn | 34.51 Bn | 959.66 Mn | 34.32% |
| 10 | Chemomab Therapeutics | 718.71 Mn | 708.34 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -33.71% |
| Sep 30, 2023 | -79.63% |
| Jun 30, 2023 | -104.68% |
| Mar 31, 2023 | -55.45% |
| Dec 31, 2022 | 1.20% |
| Sep 30, 2022 | -14.43% |
| Jun 30, 2022 | -13.35% |
| Mar 31, 2022 | -5.93% |
| Dec 31, 2021 | 6.33% |
| Sep 30, 2021 | 26.98% |
| Jun 30, 2021 | -42.96% |
| Mar 31, 2021 | 21.54% |
| Dec 31, 2020 | 6.28% |